Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Guidelines

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Formulary Central

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Rose is an associate editorial director at 

She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on 

Articles

Multidisciplinary coordination across prescribing teams, nursing, laboratory medicine, finance, and infusion centers is crucial for gene therapy delivery in Duchenne muscular dystrophy (DMD).

Consensus Guidelines Aim to Optimize DMD Gene Therapy Delivery

. Her work focuses on disparities and systemic inequities in care and access to the health system, as well as the impacts of health policy on various racial, gendered, and socioeconomic communities. She seeks perspectives from experts in internal medicine, health equity, community outreach, clinical research, mental health, and legislative policy.

, she delved into rare disease coverage at HCPLive

, a sister publication, where she fostered connections that extended beyond the research community into that of health advocacy, paving the way to her current role. Her work has been featured in 

NewsBreak, CHEST Today, Contemporary Pediatrics, Contemporary OB/GYN, Dermatology Times, Drug Topics, Managed Healthcare Executive, RamaOnHealthcare, and CGTLive.

She received her bachelor's degree in creative writing and psychology from Eckerd College and continued her postgraduate studies at the University of Florida's College of Journalism and Communications.

Initiating chronic kidney disease (CKD) screening at age 55 yielded substantial reductions in kidney failure incidence and improvements in life expectancy across all groups.

Cost-Effectiveness Analysis: CKD Screening, SGLT2 Inhibitors Can Reduce Kidney Failure Risk, Racial Disparities

Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities. 

"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health

The remote measurement tool enables Duchenne muscular dystrophy (DMD) assessments through analysis of caregiver-recorded videos. 

At-Home DMD Video Assessment Found Valid, Reliable

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

This article describes the efficacy and safety of a first-in-class treatment for adults with schizophrenia.

A novel treatment for schizophrenia has demonstrated promising efficacy and safety in adult patients. This first-in-class therapy targets specific pathways associated with the disorder, offering a new approach to managing symptoms. Clinical trials have shown significant improvements in symptom control and patient outcomes, with a favorable safety profile. The treatment's mechanism of action differs from traditional antipsychotics, potentially reducing side effects and improving patient adherence. These findings suggest a potential shift in the therapeutic landscape for schizophrenia, providing hope for improved management of this complex condition.

Managed Care Considerations for a First-in-Class M1/M4 Muscarinic Agonist for the Treatment of Adults With Schizophrenia

Supplements and Featured Publications